Skip to main content

Research Repository

Advanced Search

All Outputs (60)

Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer? (2024)
Journal Article
Mohamed, E., Fletcher, D., Hart, S., & Guinn, B.-A. (2024). Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?. Onco, 4(2), 87-100. https://doi.org/10.3390/onco4020008

Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors and their discovery rate has been increasing due to enhanced performance of chest CT scans but more than 90% are non-malignant causi... Read More about Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?.

High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study (2023)
Journal Article
Desai, S. R., Sivarasan, N., Johannson, K. A., George, P. M., Culver, D. A., Devaraj, A., Lynch, D. A., Milne, D., Renzoni, E., Nunes, H., Sverzellati, N., Spagnolo, P., Baughman, R. P., Yadav, R., Piciucchi, S., Walsh, S. L. F., Kouranos, V., Wells, A. U., Anderson, A., Morgenthau, A., …Inoue, Y. (in press). High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2823%2900267-9

One view of sarcoidosis is that the term covers many different diseases. However, no classification framework exists for the future exploration of pathogenetic pathways, genetic or trigger predilections, patterns of lung function impairment, or treat... Read More about High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study.

Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis (2023)
Journal Article
Mohamed, E., García Martínez, D. J., Hosseini, M. S., Yoong, S. Q., Fletcher, D., Hart, S., & Guinn, B. A. (2024). Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis, 45(1-2), Article bgad091. https://doi.org/10.1093/carcin/bgad091

Lung cancer (LC) causes few symptoms in the earliest stages, leading to one of the highest mortality rates among cancers. Low-dose computerised tomography (LDCT) is used to screen high-risk individuals, reducing the mortality rate by 20%. However, LD... Read More about Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis.

Respiratory Medicine (2023)
Book Chapter
Hart, S., Hearn, H., & Cookson, J. (2023). Respiratory Medicine. In K. Wong, S. Walton, S. Sudhakaran, & J. Cookson (Eds.), Practical Guide to Visualizing Medicine: A Self-Assessment Manual (153-171). Springer. https://doi.org/10.1007/978-3-031-24465-0_8

This chapter covers the main presentations of respiratory disease, breathlessness, cough, sputum production, haemoptysis, wheeze and chest pain. It shows how the diagnosis can be derived from a careful history and examination and relatively simple in... Read More about Respiratory Medicine.

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis (2023)
Journal Article
Oldham, J. M., Allen, R. J., Lorenzo-Salazar, J. M., Molyneaux, P. L., Ma, S. F., Joseph, C., Kim, J. S., Guillen-Guio, B., Hernández-Beeftink, T., Kropski, J. A., Huang, Y., Lee, C. T., Adegunsoye, A., Pugashetti, J. V., Linderholm, A. L., Vo, V., Strek, M. E., Jou, J., Muñoz-Barrera, A., Rubio-Rodriguez, L. A., …Noth, I. (2023). PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 207(11), 1515-1524. https://doi.org/10.1164/rccm.202205-0845OC

Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by limited treatment options and high mortality. A better understanding of the molecular drivers of IPF progression is needed. Objectives: To identify and validate... Read More about PCSK6 and Survival in Idiopathic Pulmonary Fibrosis.

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms (2022)
Journal Article
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

Background: The interaction between the respiratory and gastrointestinal systems, and the role of the latter in the development of respiratory pathology, has been examined with a focus on gastro-oesophageal reflux disease (GORD). However, little data... Read More about Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms.

Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings (2022)
Journal Article
Hutchinson, A., Allgar, V., Cohen, J., Currow, D. C., Griffin, S., Hart, S., Hird, K., Hodge, A., Mason, S., Northgraves, M., Reeve, J., Swan, F., & Johnson, M. J. (2022). Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings. ERJ Open Research, 8(4), Article 00257-2022. https://doi.org/10.1183/23120541.00257-2022

Introduction: One-fifth of emergency department presentations by ambulance are due to acute-on-chronic breathlessness. We explored the feasibility of an evaluation-phase, cluster randomised controlled trial (cRCT) of the effectiveness and cost-effect... Read More about Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings.

Integrated single-cell RNA sequencing analysis reveals alterations of ageing human lung endothelium heterogeneity in idiopathic pulmonary fibrosis (2022)
Preprint / Working Paper
Faulkner, E. C., Moverley, A. A., Hart, S. P., & Nikitenko, L. L. Integrated single-cell RNA sequencing analysis reveals alterations of ageing human lung endothelium heterogeneity in idiopathic pulmonary fibrosis

Increasing age is the main risk factor for chronic lung diseases (CLD) including idiopathic pulmonary fibrosis (IPF). Halting or reversing progression of IPF remains an unmet clinical need due to limited knowledge of underlying mechanisms. In particu... Read More about Integrated single-cell RNA sequencing analysis reveals alterations of ageing human lung endothelium heterogeneity in idiopathic pulmonary fibrosis.

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., Hart, S. P., Rivero, F., Allsup, D. J., & Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol (2021)
Journal Article
Northgraves, M., Cohen, J., Allgar, V., Currow, D., Hart, S., Hird, K., Hodge, A., Johnson, M., Mason, S., Swan, F., & Hutchinson, A. (2021). A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol. ERJ Open Research, 7(1), Article 00955-2020. https://doi.org/10.1183/23120541.00955-2020

Introduction: Chronic breathlessness, persistent and disabling despite optimal treatment of underlying causes, is a prevalent and frightening symptom and is associated with many emergency presentations and admission to hospital. Breathlessness manage... Read More about A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol.

Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis (2020)
Journal Article
Fraser, S. D., Crooks, M. G., Kaye, P. M., & Hart, S. P. (2021). Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis. ERJ Open Research, 7(1), https://doi.org/10.1183/23120541.00804-2020

Background: In sarcoidosis, blood monocytes, circulating precursors of granuloma macrophages, display enhanced inflammatory cytokine production, reduced expression of the regulatory (inhibitory) receptor CD200R, and altered subsets defined by CD14 an... Read More about Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis.

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study (2020)
Journal Article
Drake, T. M., Docherty, A. B., Harrison, E. M., Quint, J. K., Adamali, H., Agnew, S., Babu, S., Barber, C. M., Barratt, S., Bendstrup, E., Bianchi, S., Villegas, D. C., Chaudhuri, N., Chua, F., Coker, R., Chang, W., Crawshaw, A., Crowley, L. E., Dosanjh, D., Fiddler, C. A., …ISARIC4C Investigators. (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 202(12), 1656-1665. https://doi.org/10.1164/rccm.202007-2794OC

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established.Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporane... Read More about Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., Brindle, K., Morice, A. H., Kaye, P. M., Crooks, M. G., & Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020

Background: Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease (2020)
Journal Article
Smith, D., Du Rand, I., Addy, C. L., Collyns, T., Hart, S. P., Mitchelmore, P. J., Rahman, N. M., & Saggu, R. (2020). British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax, 75(5), 370-404. https://doi.org/10.1136/thoraxjnl-2019-213929

Summary of recommendations and good practice points
Asthma
Recommendations
Oral macrolide therapy could be considered to reduce exacerbation frequency in adults (50–70 years), with ongoing symptoms despite >80% adherence to high-dose inhaled stero... Read More about British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease.

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M. J., Bajwah, S., Lovell, N., Yi, D., Hart, S., Crosby, V., Poad, H., Currow, D., Best, E., & Brown, S. (2020). Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 75(2), 176-179. https://doi.org/10.1136/thoraxjnl-2019-213879

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with... Read More about Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).